98%
921
2 minutes
20
Objective: To investigate the effect of butylphthalide combined with fasudil in the treatment of subarachnoid hemorrhage (SAH) with cerebral vasospasm (CVS) on inflammatory factors, cognitive function and vascular endothelial function.
Methods: It is a retrospective study in which a total of 104 patients with SAH with CVS admitted to Baoding First Central Hospital from July 2020 to February 2022 were selected and randomly divided into two groups by drawing lots. Patients in the control group were treated with basic symptomatic treatment, while those in the observation group were treated with butylphthalide soft capsule combined with fasudil hydrochloride injection on the basis of the control group. Before and after treatment, serum neuron specific enolase (NSE), tumor necrosis factor-α(TNF-α), interleukin-8(IL-8), hypersensitive C-reactive protein (CRP), Birmingham Cognitive Screen test (BCoS) score, serum soluble intercellular adhesion molecule-1(ICAM-1), serum endothelin-1(ET-1), vascular endothelial growth factor (VEGF) levels, and endothelium-dependent vasodilation function (FMD) in the two groups were compared.
Results: After treatment, the expression levels of NSE, TNF-α, IL-8 and CRP in the two groups were significantly decreased, and the expression levels of all indicators in the observation group were lower than that in the control group (p<0.05). After treatment, the scores of orientations, attention, memory, language, practice and action in the two groups were significantly increased, and the scores of all dimensions in the observation group were higher than those in the control group (p<0.05). After treatment, S-ICAM-1, ET-1, VEGF, FMD decreased in both groups, and all indicators of the observation group were lower than those of the control group, with statistically significant differences (p<0.05).
Conclusion: Butylphthalide combined with fasudil therapy was found as effective in reducing inflammatory factors, ameliorating cognitive function and vascular endothelial function in patients with subarachnoid hemorrhage complicated with cerebral vasospasm.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626066 | PMC |
http://dx.doi.org/10.12669/pjms.39.6.6768 | DOI Listing |
Aging Dis
June 2025
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
Post-recanalization microcirculation dysfunction is common and significantly contributes to poor outcomes in ischemic stroke. Pericytes have been shown to mediate the "no-reflow" phenomenon by constricting capillaries in experimental stroke models, implicating their critical role in early microcirculation dysfunction. However, little is known about the long-term fate of pericytes and their contribution to sustained microcirculation dysfunction in prolonged period of time.
View Article and Find Full Text PDFMedicine (Baltimore)
May 2025
Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Fasudil hydrochloride is used as a therapeutic agent for cerebral vasospasm after aneurysmal subarachnoid hemorrhage surgery; however, its limited efficacy necessitates additional treatment options. Although the therapeutic potential of cilostazol for improved outcomes after aneurysmal subarachnoid hemorrhage has been reported, no clinical studies have examined the effects of administering both cilostazol and fasudil hydrochloride on mortality and physical disability in patients. Therefore, we investigated the impact of combined fasudil hydrochloride and cilostazol administration among patients with subarachnoid hemorrhage (SAH) in Japan.
View Article and Find Full Text PDFPharmaceuticals (Basel)
April 2025
National Institute for Health and Care Research Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London Institute of Ophthalmology, London EC1V 2PD, UK.
: Primary open-angle glaucoma (POAG) is an anterior optic neuropathy that can lead to irreversible vision loss if untreated. Prostaglandin analogues are the first-line treatment, but new drug classes, such as rho kinase (ROCK) inhibitors, are being explored. This review evaluates the efficacy and safety of ROCK inhibitors in treating POAG based on completed trials, comparing results with available natural history data and identifying areas for further research.
View Article and Find Full Text PDFJ Clin Med
April 2025
Department of Neurosurgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Mie, Japan.
: The outcome for aneurysmal subarachnoid hemorrhage (SAH) remains poor, particularly for patients presenting with World Federation of Neurological Surgeons (WFNS) grades IV-V. This study was designed to identify independent prognostic factors in this group of patients with poor-grade SAH. : We prospectively analyzed 357 SAH patients with admission WFNS grades IV-V enrolled in nine primary stroke centers in Mie prefecture, Japan, from 2013 to 2022.
View Article and Find Full Text PDFSurv Ophthalmol
July 2025
National Institute for Health and Care Research Biomedical Research Centre for Ophthalmology Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK. Electronic address:
The therapeutic potential of rho kinase (ROCK) inhibitors in ophthalmology is gaining attention, given their multifaceted role in cellular regulation, particularly within ocular pathologies. This review synthesizes findings from clinical and preclinical studies on the efficacy and safety of ROCK inhibitors across glaucoma, corneal, and retinal diseases. We performed a systematic database search in Ovid MEDLINE and Ovid Embase on 5th April 2022 using the following keywords: 'primary open angle glaucoma', 'glaucoma surgery', 'corneal wound healing', 'corneal endothelial dysfunction', 'diabetic retinopathy', 'diabetic macular oedema', 'age-related macular degeneration', 'rho kinase inhibitor', 'rho-kinase inhibitor', rock inhibitor', 'ripasudil', 'netarsudil' and 'fasudil'.
View Article and Find Full Text PDF